Biotechnology and Bioprocess Engineering

, Volume 12, Issue 3, pp 282–288 | Cite as

Generation of a naïve/synthetic antibody specific to botulinum neurotoxin via motif-grafting

  • Ji-Chul Lee
  • Sun-Young Park
  • Cha-Yong Choi
  • Junho Chung
  • Myung-Shin Lee


In this study, we describe a new approach to the production of naïve/synthetic human antibodies against the botulinum neurotoxin (BoNT). First, peptides that bind to BoNT serotype A (BoNT/A) were screened from a phage display of a combinatorial peptide library. One peptide, designated ANT 12-2 (TLPSPLALLTVH), was determined to interact with BoNT/A, as well as with other serotypes of BoNT. This peptide specifically reacted with the native form of BoNT/A, but not with its formalin-inactivated form. Next, a hybrid naïve/synthetic human Fab library was generated via the grafting of a peptide motif from ANT 12-2 into HCDR3 with randomized flanking residues. Through biopanning, the Fab clone, ANTHU-1, which harbors the HCDR3 sequence of VRIQRSPLALLSWGDV, was selected and confirmed in order to retain the same BoNT-binding characteristics as ANT 12-2.


botulinum neurotoxin antibody phage display peptide library 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gill, D. M. (1982) Bacterial toxins: A table of lethal amounts.Microbiol. Rev. 46: 86–94.Google Scholar
  2. 2.
    Roy, M. J. (2004)Physician's Guide to Terrorist Attack Humana Press, Totowa, NJ, USA.Google Scholar
  3. 3.
    Pearce, L. B., E. R. First, R. D. MacCallum, and A. Gupta (1997) Pharmacologic characterization of botulinum toxin for basic science and medicine.Toxicon 35: 1373–1412.CrossRefGoogle Scholar
  4. 4.
    Singh, B. R., T. Lopes, and M. A. Silvia (1996) Immunochemical characterization of type A botulinum neurotoxin in its purified and complexed forms.Toxicon 34: 267–275.CrossRefGoogle Scholar
  5. 5.
    Arnon, S. S., R. Schechter, T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, J. Hauer, M. Layton, S. Lillibridge, M. T. Osterholm, T. O'Toole, G. Parker, T. M. Perl, P. K. Russell, D. L. Swerdlow, and K. Tonat (2004) Botulinum toxin as a biological weapon: Medical and public health management.JAMA 285: 1059–1070.CrossRefGoogle Scholar
  6. 6.
    Mullaney, B. P., M. G. Pallavicini, and J. D. Marks (2001) Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display.Infect. Immun. 69: 6511–6514.CrossRefGoogle Scholar
  7. 7.
    Pless, D. D., E. R. Torres, E. K. Reinke, and S. Bavari (2001) High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A.Infect. Immun. 69: 570–574.CrossRefGoogle Scholar
  8. 8.
    Wu, H. C., C. T. Yeh, Y. L. Huang, L. J. Tarn, and C. C. Lung (2001) Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on theClostridium botulinum neurotoxin type A.Appl. Environ. Microbiol. 67: 3201–3207.CrossRefGoogle Scholar
  9. 9.
    Nowakowski, A., C. Wang, D. B. Powers, P. Amersdorfer, T. J. Smith, V. A. Montgomery, R. Sheridan, R. Blake, L. A. Smith, and J. D. Marks (2002) Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.Proc. Natl. Acad. Sci. USA 99: 11346–11350.CrossRefGoogle Scholar
  10. 10.
    Mah, D. C., W. G. Hu, J. K. Pon, S. A. Masri, R. E. Fulton, P. L. Monette, and L. P. Nagata (2003) Recombinant anti-botulinum neurotoxin A single-chain variable fragment antibody generated using a phage display system.Hybrid. Hybridomics 22: 277–283.CrossRefGoogle Scholar
  11. 11.
    Marks, J. D. (2004) Deciphering antibody properties that lead to potent bofulinum neurotoxin neutralization.Mov. Disord. 19 Suppl 8: S101–108.CrossRefGoogle Scholar
  12. 12.
    Yang, G. H., K. S. Kim, H. W. Kim, S. T. Jeong, G. H. Huh, J. C. Kim, and H. H. Jung (2004) Isolation and characterization of a neutralizing antibody specific to internalization domain ofClostridium botulinum neurotoxin type B.Toxicon 44: 19–25.CrossRefGoogle Scholar
  13. 13.
    Chung, J., C. Rader, M. Popkov, Y. M. Hur, H. K. Kim, Y. J. Lee, and C. F. Barbas, 3rd (2004) Integrin alphaiibbeta3-specific synthetic human monoclonal anti bodies and HCDR3 peptides that potently inhibit platelet aggregation.FASEB J. 18: 361–363.CrossRefGoogle Scholar
  14. 14.
    Torii, Y., Y. Tokumaru, S. Kawaguchi, N. Izumi, S. Maruyama, M. Mukamoto, S. Kozaki, and M. Takahashi (2002) Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid.Vaccine 20: 2556–2561.CrossRefGoogle Scholar
  15. 15.
    Barbas, C. F., 3rd, J. D. Bain, D. M. Hoekstra, and R. A. Lerner (1992) Semisynthetic combinatorial antibody libraries: A chemical solution to the diversity problem.Proc. Natl. Acad. Sci. USA 89: 4457–4461.CrossRefGoogle Scholar
  16. 16.
    Persson, M. A., R. H. Caothien, and D. R. Burton (1991) Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning.Proc. Natl. Acad. Sci. USA 88: 2432–2436.CrossRefGoogle Scholar
  17. 17.
    Barbas, C. F., 3rd, D. R. Burton, J. K. Scott, and G. J. Silverman (2001)Phage Display: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA.Google Scholar
  18. 18.
    Zdanovsky, A. G., N. V. Karassina, D. Simpson, and M. V. Zdanovskaia (2001) Peptide phage display library as source for inhibitors of clostridial neurotoxins.J. Protein Chem. 20: 73–80.CrossRefGoogle Scholar
  19. 19.
    Hynes, R. O. (1987) Integrins: A family of cell surface receptors.Cell 48: 549–554.CrossRefGoogle Scholar
  20. 20.
    Ruoslahti, E. and M. D. Pierschbacher (1987) New perspectives in cell adhesion: RGD and integrins.Science 238: 491–497.CrossRefGoogle Scholar
  21. 21.
    Albelda, S. M. and C. A. Buck (1990) Integrins and other cell adhesion molecules.FASEB J. 4: 2868–2880.Google Scholar
  22. 22.
    Hynes, R. O. (1992) Integrins: Versatility, modulation, and signaling in cell adhesion.Cell 69: 11–25.CrossRefGoogle Scholar

Copyright information

© The Korean Society for Biotechnology and Bioengineering 2007

Authors and Affiliations

  1. 1.Interdisciplinary Program of Biochemical Engineering and BiotechnologySeoul National UniversitySeoulKorea
  2. 2.Department of Biochemistry and Molecular Biology and Cancer Research InstituteSeoul National University College of MedicineSeoulKorea
  3. 3.The Armed Forces Medical Research InstituteDaejeonKorea

Personalised recommendations